Asset Details
Do you wish to reserve the book?
The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity
Do you wish to request the book?
The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity
2023
Overview
Objective To investigate the effects of secukinumab treatment for psoriasis on different functional cytokines and inflammatory mediators in patients’ serum Methods Enzyme‐linked immunosorbent assay was used to detect interleukin (IL)‐1β and IL‐1RA associated with intrinsic immunity; IL‐6, IL‐18, and growth regulated oncogene alpha (GROα) associated with neutrophils; IL‐12, tumour necrosis factor (TNF)‐α, and interferon (IFN)‐γ associated with Th1; IL‐23, IL‐17A, and IL‐22 associated with Th17; Thymus activation regulated chemokine (TARC), IL‐13, and defensin beta 2 (DEFB2) associated with Th2; Vascular endothelial growth factor (VEGF)‐A and IL‐10 associated with angiogenesis; and IFN‐γ associated with sepsis in the peripheral blood of 12 patients with common psoriasis treated with secukinumab and 15 healthy controls. IL‐23, IL‐17A, IL‐22 associated with Th17; TARC, IL‐13, DEFB2 associated with Th2; VEGF‐A, IL‐10 associated with angiogenesis and procalcitonin (PCT) associated with sepsis. The differences in expression of the above cytokines before and after treatment and the correlation with psoriasis disease severity［Psoriasis Area Severity Index(PASI) score］, age, and disease duration were analyzed. Results The mean PASI score of the enrolled patients with moderate to severe psoriasis was 21.6 ± 11.0 before treatment and decreased to below 1 after treatment. Serum IL‐6; IL‐18, GROα, IFN‐γ, TNF‐α, VEGF‐A, and IL‐17A were significantly higher than normal. And IL‐17A and IFN‐γ were positively correlated with disease duration and age, and IL‐18 was positively correlated with PASI score. The expression levels of IL‐6, GROα, VEGF‐A, IFN‐γ, TNF‐α, IL‐17A and IL‐23 were significantly lower after secukinumab treatment compared with those before treatment, but the expression levels of IFN‐γ, VEGF‐A, TARC, IL‐13, and DEFB2 were still significantly higher than those of normal subjects after treatment Conclusions secukinumab clears skin lesions by antagonizing IL‐17A and simultaneously decreasing the expression levels of IL‐6, GRO α, VEGF‐A, IFN‐γ, TNF‐α, IL‐17A, and IL‐23.
Subject
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized - pharmacology
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ DEFB2
/ Female
/ Humans
/ IFN‐ γ
/ IL‐1 β
/ IL‐10
/ IL‐12
/ IL‐13
/ IL‐17A
/ IL‐18
/ IL‐1RA
/ IL‐22
/ IL‐23
/ IL‐6
/ Male
/ PCT
/ TARC
/ TNF‐ α
/ VEGF‐A
